Table 3.
Distribution of industry payments by cohort. Values are number (percentage) unless stated otherwise
| CSPC (n=9799) | GCSF (n=271 485) | Nab-paclitaxel (n=86 394) | Branded drug (n=13 386) | |
|---|---|---|---|---|
| Oncologist received payment during 365 days before index date | 2962 (30.2) | 76 747 (28.3) | 18 491 (21.4) | 4170 (31.2) |
| No of payments among those who received any payments: | ||||
| Mean | 6.3 | 6.1 | 6.5 | 12.9 |
| Median (IQR) | 4 (6) | 4 (6) | 4 (6) | 7 (16) |
| $ value of payments among those who received any payments: | ||||
| Mean | 589 | 219 | 1356 | 1267 |
| Median (IQR) | 63 (95) | 60 (83) | 89 (182) | 156 (301) |
| Oncologist received payment during 365 days before index date, by calendar year of index date: | ||||
| 2014 | 464 (32.3) | 15 996 (30.5) | 4553 (26.3) | 0 |
| 2015 | 469 (30.6) | 14 657 (29.8) | 4058 (25.1) | 0 |
| 2016 | 535 (30.8) | 13 578 (29.3) | 3424 (22.6) | 221 (55.4) |
| 2017 | 504 (28.9) | 11 917 (27.6) | 2811 (20.7) | 214 (49.9) |
| 2018 | 554 (31.3) | 11 494 (27.0) | 2298 (17.5) | 2093 (38.7) |
| 2019 | 436 (27.5) | 9105 (24.1) | 1347 (12.2) | 1642 (23.0) |
$
1.00 (£0.81; €0.94).
CSPC=castration sensitive prostate cancer; GCSF=granulocyte colony stimulating factors; IQR=interquartile range.